Alvaro Javier Feliz Morel

Mr. Alvaro Javier Feliz Morel

Exiris SRL, Rome, Lazio, Italy
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 October 2022 in European Journal of Pharmacology
Verified
Journal Article
Closed access
Margherita BrindisiMargherita Brindisi
Margherita Brindisi
SBSimona Barone
Simona Barone
ARAlice Rossi
Alice Rossi
ECEmilia Cassese
Emilia Cassese
NGNunzio Del Gaudio
Nunzio Del Gaudio
VSVincenzo Summa
Vincenzo Summa

5 May 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Alvaro Javier Feliz MorelAlvaro Javier Feliz Morel
Alvaro Javier Feliz Morel
AHAnida Hasanovic
Anida Hasanovic
AMAurélie Morin
Aurélie Morin
Chloé PrunierChloé Prunier
Chloé Prunier
VMVirginie Magnone
Virginie Magnone
Isabelle Mus-VeteauIsabelle Mus-Veteau
Isabelle Mus-Veteau
Despite the development of new therapeutic strategies, cancer remains one of the leading causes of mortality worldwide. One of the current major challenges is the resistance of cancers to chemotherapy treatments inducing metastases and relapse of the tumor. The Hedgehog receptor Patched (Ptch1) is overexpressed in many types of cancers. We showed that Ptch1 contributes to the efflux of doxorubicin and plays an important role in the resistance to chemotherapy in adrenocortical carcinoma (ACC), a rare cancer which presents strong resistance to the standard of care chemotherapy treatment. In the present study, we isolated and characterized a subpopulation of the ACC cell line H295R in which Ptch1 is overexpressed and more present at the cell surface. This cell subpopulation is more resistant to doxorubicin, grows as spheroids, and has a greater capability of clonogenicity, migration, and invasion than the parental cells. Xenograft experiments performed in mice and in ovo showed that this cell subpopulation is more tumorigenic and metastatic than the parental cells. These results suggest that this cell subpopulation has cancer stem-like or persistent cell properties which were strengthened by RNA-seq. If present in tumors from ACC patients, these cells could be responsible for therapy resistance, relapse, and metastases.

7 December 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
MPManon Penco-Campillo
Manon Penco-Campillo
YCYannick Comoglio
Yannick Comoglio
Alvaro Javier Feliz MorelAlvaro Javier Feliz Morel
Alvaro Javier Feliz Morel
RHRita Hanna
Rita Hanna
JDJérôme Durivault
Jérôme Durivault
GPGilles Pagès
Gilles Pagès
A Correction to this paper has been published: https://doi.org/10.1038/s42003-020-01502-2.